RESUMEN
Keratoacanthoma (KA) and well-differentiated cutaneous squamous cell carcinoma (cSCC) are hardly distinguishable clinically and histologically. They both can be seen in patients with hereditary non-polyposis colorectal cancer (HNPCC) or Lynch Syndrome, corresponding to DNA microsatellite instability. In our case, a young man had the excision of two rapidly growing skin tumours for which distinction between KA and cSCC was initially clinically and pathologically challenging. The diagnosis of well-differentiated cSCCs was made and the patient was treated with surgery. Ten years after the first cSCC, he was diagnosed with Muir-Torre syndrome, a variant of Lynch syndrome, with an heterozygote mutation of the MSH2 gene. This later diagnosis allowed to screen his family members for the same mutation and to adopt an appropriate follow-up regarding the risk of digestive tumours for him and his family. Furthermore, it is important to know that, in case of non-resectable cSCC occurring in this patient, immunotherapy using anti-PD1 antibody would probably be effective due to the known increased immunogenicity of MMR deficient tumours.
Asunto(s)
Carcinoma de Células Escamosas , Queratoacantoma , Síndrome de Muir-Torre , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/cirugía , Reparación de la Incompatibilidad de ADN/genética , Humanos , Queratoacantoma/diagnóstico , Queratoacantoma/genética , Queratoacantoma/cirugía , Masculino , Síndrome de Muir-Torre/diagnóstico , Síndrome de Muir-Torre/genética , Proteína 2 Homóloga a MutS/genéticaRESUMEN
INTRODUCTION: Development of acral malignant melanoma in Mal de Meleda is highly unusual. As far as we could ascertain, to date, only 10 previous cases have been published. Herein, we report a new case. OBSERVATION: A 64-year-old Algerian man was followed for familial Mal de Meleda. The diagnosis was based on clinical presentation as he had a non-syndromic hereditary foul-smelling and yellowish palmoplantar keratoderma transgrediens. After the failure of acitretin, which had not prevented retractile and mutilating progression of the palmoplantar keratoderma, he had undergone surgery with graft excision of both palms. At the age of 59 years, he presented a tumor on the dorsal aspect of the 1st phalanx of the 3rd finger of the right hand in a non-grafted area. The diagnosis of acral melanoma was confirmed histologically. The radiological findings showed a specific homolateral axillary adenopathy. He underwent digital amputation of the 3rd finger, with lymph node dissection and chemotherapy involving dacarbazine. Follow-up at 5 years showed complete remission of the melanoma. DISCUSSION: Mal de Meleda is a hereditary palmoplantar keratoderma due to mutation of the SLURP1 gene. Clinical diagnosis is based on the typical phenotype in adulthood. The occurrence of acral melanoma, which is a rare form of melanoma (1 to 7%), especially in the fingers, together with an unusual palmoplantar keratoderma in a subject of type IV phototype does not appear to be a chance event. This association seems to be the outcome of immune dysregulation rather than of chronic inflammation.
Asunto(s)
Dedos/patología , Queratodermia Palmoplantar/patología , Melanoma/patología , Neoplasias Cutáneas/patología , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Clorhidrato de Fingolimod/uso terapéutico , Inmunosupresores/uso terapéutico , Melanoma/diagnóstico , Esclerosis Múltiple/tratamiento farmacológico , Neoplasias Cutáneas/diagnóstico , Dorso , Femenino , Humanos , Factores Inmunológicos/uso terapéutico , Melanoma/inmunología , Persona de Mediana Edad , Natalizumab/uso terapéutico , Factores de Riesgo , Neoplasias Cutáneas/inmunologíaAsunto(s)
Antineoplásicos/efectos adversos , Melanoma/tratamiento farmacológico , Terapia Molecular Dirigida/efectos adversos , Polineuropatías/inducido químicamente , Neoplasias Cutáneas/tratamiento farmacológico , Anciano , Azetidinas/efectos adversos , Femenino , Humanos , Imidazoles/efectos adversos , Masculino , Persona de Mediana Edad , Terapia Molecular Dirigida/métodos , Oximas/efectos adversos , Piperidinas/efectos adversos , Piridonas/efectos adversos , Pirimidinonas/efectos adversos , Vemurafenib/efectos adversosRESUMEN
PURPOSE: Sentinel lymph node biopsy (SLNB) is now a standard of care for cutaneous melanoma, but it is still controversial for cutaneous head and neck melanoma (CHNM). This study aims to confirm the feasibility, accuracy and low morbidity of SLNB in CHNM and evaluate its prognostic value. METHODS: A monocentric and retrospective study on patients with CHNM treated in our tertiary care center (Gustave Roussy) between January 2008 and December 2012 was performed. The feasibility, morbidity and prognostic value of this technique were analysed. RESULTS: One hundred and twenty-four consecutive patients were included. SLNB was realized in 97.6% of the cases. No significant post-operative morbidity was observed. Nineteen percents of patients had a positive SN while only 14.3% of complete lymph node dissections (CLND) had additional nodal metastasis. The risk of recurrence after positive SN was significantly higher (69.2 vs 30.8%, p = 0.043). The false omission rate was low with 7.1%. Overall survival and disease-free survival were better in the negative SN group (82 vs 49%, p < 0.001 and 69.3 vs 41.8%, p = 0.0131). The risk of recurrence was significantly higher in the positive SN group (p = 0.043) and when primary tumour was ulcerated (p = 0.031). Only the mitotic rate of the primary tumour was associated with SN positivity (p = 0.049). CONCLUSION: As in other sites, SLNB status is a strong prognostic factor with comparable false omission rate and no superior morbidity.
Asunto(s)
Neoplasias de Cabeza y Cuello , Escisión del Ganglio Linfático/métodos , Melanoma , Biopsia del Ganglio Linfático Centinela/métodos , Neoplasias Cutáneas , Supervivencia sin Enfermedad , Femenino , Francia/epidemiología , Neoplasias de Cabeza y Cuello/epidemiología , Neoplasias de Cabeza y Cuello/patología , Neoplasias de Cabeza y Cuello/cirugía , Humanos , Masculino , Melanoma/epidemiología , Melanoma/patología , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Pronóstico , Estudios Retrospectivos , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/patología , Centros de Atención Terciaria/estadística & datos numéricos , Melanoma Cutáneo MalignoRESUMEN
BACKGROUND: Ipilimumab, an immune checkpoint inhibitor targeting CTLA-4, prolongs survival in a subset of patients with metastatic melanoma (MM) but can induce immune-related adverse events, including enterocolitis. We hypothesized that baseline gut microbiota could predict ipilimumab anti-tumor response and/or intestinal toxicity. PATIENTS AND METHODS: Twenty-six patients with MM treated with ipilimumab were prospectively enrolled. Fecal microbiota composition was assessed using 16S rRNA gene sequencing at baseline and before each ipilimumab infusion. Patients were further clustered based on microbiota patterns. Peripheral blood lymphocytes immunophenotypes were studied in parallel. RESULTS: A distinct baseline gut microbiota composition was associated with both clinical response and colitis. Compared with patients whose baseline microbiota was driven by Bacteroides (cluster B, n = 10), patients whose baseline microbiota was enriched with Faecalibacterium genus and other Firmicutes (cluster A, n = 12) had longer progression-free survival (P = 0.0039) and overall survival (P = 0.051). Most of the baseline colitis-associated phylotypes were related to Firmicutes (e.g. relatives of Faecalibacterium prausnitzii and Gemmiger formicilis), whereas no colitis-related phylotypes were assigned to Bacteroidetes. A low proportion of peripheral blood regulatory T cells was associated with cluster A, long-term clinical benefit and colitis. Ipilimumab led to a higher inducible T-cell COStimulator induction on CD4+ T cells and to a higher increase in serum CD25 in patients who belonged to Faecalibacterium-driven cluster A. CONCLUSION: Baseline gut microbiota enriched with Faecalibacterium and other Firmicutes is associated with beneficial clinical response to ipilimumab and more frequent occurrence of ipilimumab-induced colitis.
Asunto(s)
Antineoplásicos Inmunológicos/uso terapéutico , Colitis/complicaciones , Intestinos/microbiología , Ipilimumab/uso terapéutico , Melanoma/tratamiento farmacológico , Microbiota , Anciano , Colitis/microbiología , Femenino , Humanos , Masculino , Melanoma/complicaciones , Melanoma/microbiología , Melanoma/patología , Metástasis de la Neoplasia , Estudios Prospectivos , ARN Ribosómico 16S/genéticaRESUMEN
BACKGROUND: Refractory locally advanced or metastatic nonmelanoma skin cancer (NMSC) is a frequent therapeutic impasse. OBJECTIVES: To address the question of the efficacy of induction therapy with cetuximab as neoadjuvant treatment for locally advanced NMSC. METHODS: From 2008 to 2013, all patients with a diagnosis of unresectable locally advanced skin squamous cell carcinoma were treated with neoadjuvant cetuximab alone (CM) or combined with a platinum salt and 5-fluorouracil (CC). Resectability, and clinical and pathological response, as well as relapse-free and overall survival were evaluated. RESULTS: Thirty-four patients, with a median age of 74·5 years, were evaluated. Twenty-five patients received CC. After three cycles of CC, 23 of 25 patients whose tumours were initially unresectable became amenable to surgery (92%). A complete histological response was observed in 15 (65%) patients. The mean progression-free and mean overall survival in operated patients were 8·5 and 26·0 months, respectively. CONCLUSIONS: There was a good response in terms of resectability and tumour control in the majority of patients, with few relapses, despite the initially poor prognosis of these tumours in this elderly group of patients. However, this therapeutic strategy needs to be validated in a prospective, randomized study.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Anciano , Cetuximab/administración & dosificación , Cetuximab/efectos adversos , Quimioterapia Adyuvante , Cisplatino/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Foliculitis/inducido químicamente , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
BACKGROUND: BRAF inhibitors are being developed for the treatment of metastatic melanoma harboring a V600E mutation. The use of vemurafenib significantly increases progression-free survival (PFS) and overall survival (OS) in this population of patients, but is associated with numerous adverse skin reactions. PATIENTS AND METHODS: We carried out a systematic dermatologic study of 42 patients treated with vemurafenib. We collected detailed dermatologic symptoms, photos and biopsy specimens of the skin lesions which enabled us to classify the side-effects. The management and evolution of the skin symptoms are also reported. RESULTS: All patients presented with at least one adverse skin reaction. The most common cutaneous side-effects consisted in verrucous papillomas (79%) and hand-foot skin reaction (60%). Other common cutaneous toxic effects were a diffuse hyperkeratotic perifollicular rash (55%), photosensitivity (52%) and alopecia (45%). Epidermoid cysts (33%) and eruptive nevi (10%) were also observed. Keratoacanthomas (KA) and squamous cell carcinoma (SCC) occurred in 14% and 26% of the patients, respectively. CONCLUSIONS: These cutaneous side-effects are cause of concern due to their intrinsic potential for malignancy or because of their impact on patients' quality of life. Management of this skin toxicity relies on symptomatic measures and sun photoprotection.
Asunto(s)
Indoles/administración & dosificación , Indoles/efectos adversos , Proteínas Proto-Oncogénicas B-raf/antagonistas & inhibidores , Neoplasias Cutáneas/tratamiento farmacológico , Piel/efectos de los fármacos , Piel/patología , Sulfonamidas/administración & dosificación , Sulfonamidas/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Proteínas Proto-Oncogénicas B-raf/metabolismo , Piel/metabolismo , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/diagnóstico , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/patología , VemurafenibRESUMEN
BACKGROUND: Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overall survival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in a compassionate-use program. PATIENTS AND METHODS: In this prospective study, patients were treated between June 2010 and September 2011. Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy, and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kg every 3 weeks. RESULTS: Seventy-three patients were included. Median OS was 9.1 months (95% CI 6.4-11.3) from the start of ipilimumab. Immune-related adverse events were observed in 45 patients (62%), including 19 grade 3-4 events (26%). No drug-related death occurred. A lymphocyte count >1000/mm(3) at the start of the second course and an increase in the eosinophil count >100/mm(3) between the first and second infusions were correlated with an improved OS. CONCLUSION: Ipilimumab toxic effect is manageable in real life. Biological data such as lymphocyte and eosinophil counts at the time of the second ipilimumab infusion appear to be early markers associated with better OS.
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Eosinófilos/metabolismo , Linfocitos/metabolismo , Melanoma/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Eosinófilos/efectos de los fármacos , Eosinófilos/patología , Femenino , Humanos , Ipilimumab , Recuento de Linfocitos , Linfocitos/efectos de los fármacos , Linfocitos/patología , Masculino , Melanoma/mortalidad , Melanoma/patología , Persona de Mediana Edad , Estudios Prospectivos , Neoplasias Cutáneas/mortalidad , Neoplasias Cutáneas/patología , Tasa de Supervivencia/tendencias , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Sequential tumour biopsies are of potential interest for the rational development of molecular targeted therapies. PATIENTS AND METHODS: From June 2004 to July 2009, 186 patients participated in 14 phase I clinical trials in which sequential tumour biopsies (13 trials) and/or sequential normal skin biopsies (6 trials) were optional. All patients had to sign an independent informed consent for the biopsies. RESULTS: Tumour biopsies were proposed to 155 patients and 130 (84%) signed the consent while normal skin biopsies were proposed to 70 patients and 57 (81%) signed the consent. Tumour biopsies could not be carried out in 41 (31%) of the 130 consenting patients. Tumour biopsies were collected at baseline in 33 patients, at baseline and under treatment in 56 patients. Tumour biopsies were obtained using an 18-gauge needle, under ultrasound or computed tomography guidance. Only nine minor complications were recorded. Most tumour biopsy samples collected were intended for ancillary molecular studies including protein or gene expression analysis, comparative genomic hybridization array or DNA sequencing. According to the results available, 70% of the biopsy samples met the quality criteria of each study and were suitable for ancillary studies. CONCLUSIONS: In our experience, the majority of the patients accepted skin biopsies as well as tumour biopsies. Sequential tumour and skin biopsies are feasible and safe during early-phase clinical trials, even when patients are exposed to anti-angiogenic agents. The real scientific value of such biopsies for dose selection in phase I trials has yet to be established.
Asunto(s)
Investigación Biomédica/métodos , Ensayos Clínicos Fase I como Asunto/efectos adversos , Ensayos Clínicos Fase I como Asunto/métodos , Neoplasias/patología , Aceptación de la Atención de Salud , Piel/patología , Adolescente , Adulto , Anciano , Algoritmos , Biopsia/efectos adversos , Biopsia/métodos , Biopsia/psicología , Biopsia/estadística & datos numéricos , Ensayos Clínicos Fase I como Asunto/psicología , Estudios de Factibilidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Aceptación de la Atención de Salud/psicología , Seguridad del Paciente/estadística & datos numéricos , Adulto JovenRESUMEN
BACKGROUND: Psoas abscess is a rare clinical entity that occurs chiefly after intra-abdominal or retroperitoneal infection. We report two cases of psoas abscesses caused by group A beta-haemolytic streptococcal infection having a cutaneous portal of entry. CASE REPORTS: The first patient, a 50-year-old man, was feverish and had ulcerative and necrotic cutaneous lesions evocative of ecthyma that were progressing for three months and were recently associated with a painful mass in the left iliac fossa, leading to difficulties in walking. The second patient, a 35-year-old woman with a medical history of intravenous drug addiction, was admitted to intensive care for sepsis syndrome following group A beta-haemolytic streptococcal infection with a cutaneous portal of entry (swelling on left lower limb). She remained unaccountably subfebrile 10 days after the start of antibiotic therapy with amoxicillin. Abdominal CAT scans for each patient confirmed the diagnosis of left psoas abscess. For the first patient, the same group A beta-haemolytic streptococcus was isolated in drainage fluid and at the cutaneous injury site. The outcome was favourable in both cases following extensive intravenous antibiotic therapy (amoxicillin) combined with percutaneous drainage (in the first case). DISCUSSION: Psoas abscess can occur after locoregional infection and the portals of entry are usually gastro-intestinal, musculoskeletal or genitourinary, with many organisms capable of causing such secondary abscesses. Psoas abscess can also be a primary clinical event. Staphylococcus aureus is the most common causative organism. The presented cases comprised secondary psoas abscesses with a cutaneous portal of entry. Since the complete set of three evocative symptoms (prolonged fever, pain and psoitis) is frequently seen late, diagnosis must be made on the basis of prolonged infectious state or unaccountable feverish abdominal pain. Diagnosis is based on abdominal CAT scan and treatment involves the use of appropriate antibiotics as well as percutaneous or surgical drainage of the abscess. The mortality rate in this patient population remains high with survival being dependent on prompt initiation of therapy.